Entero Therapeutics
Entero Therapeutics
ENTO
NASDAQ
0.41
USD
-33.87%
About
First Wave BioPharma, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the research and development of targeted, non-systemic therapies for the treatment of patients with gastrointestinal (GI) diseases. It is focused on developing a therapeutic pipeline with multiple late-stage clinical programs built around three proprietary technologies: Latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides; the biologic Adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency, and Capeserod, a selective 5-HT4 receptor partial agonist which the Company is developing as a gastroparesis therapeutic..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 282.1K |
| Three Month Average Volume | 11.9M |
| High Low | |
| Fifty-Two Week High | 22.2 USD |
| Fifty-Two Week Low | 0.185 USD |
| Fifty-Two Week High Date | 14 Sep 2023 |
| Fifty-Two Week Low Date | 08 Aug 2024 |
| Price and Volume | |
| Current Price | 0.4101 USD |
| Beta | 1 |
| Relative Price Change | |
| Four Week Relative Price Change | -39.51% |
| Thirteen Week Relative Price Change | -85.81% |
| Twenty-Six Week Relative Price Change | -95.96% |
| Fifty-Two Week Relative Price Change | -94.72% |
| Year-to-Date Relative Price Change | -91.75% |
| Price Change | |
| One Day Price Change | -1.67% |
| Thirteen Week Price Change | -84.81% |
| Twenty-Six Week Price Change | -95.56% |
| Five Day Price Change | -0.44% |
| Fifty-Two Week Price Change | -93.39% |
| Year-to-Date Price Change | -90.24% |
| Month-to-Date Price Change | -41.41% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 2.30809 USD |
| Book Value Per Share (Most Recent Quarter) | 38.44734 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 1.22918 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | -2.73555 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -5.2964 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0 USD |
| Revenue Per Share (Trailing Twelve Months) | 0 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -47.87719 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -51.90039 USD |
| Normalized (Last Fiscal Year) | -47.87719 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -47.87719 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -49.16169 USD |
| Including Extraordinary Items (Last Fiscal Year) | -47.87719 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -51.90039 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 2.37782 USD |
| Cash Per Share (Most Recent Quarter) | 1.69459 USD |
| Cash Flow Per Share (Last Fiscal Year) | -47.79045 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -1.62424 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -3.36521 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -100,000 |
| Cash Flow Revenue (Trailing Twelve Months) | -100,000 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -99,999.99% |
| Pretax Margin (Last Fiscal Year) | -99,999.99% |
| Pretax Margin (5 Year) | -99,999.99% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -99,999.99% |
| Operating Margin (Trailing Twelve Months) | -99,999.99% |
| Operating Margin (5 Year) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -99,999.99% |
| Net Profit Margin (Trailing Twelve Months) | -99,999.99% |
| Net Profit Margin (5 Year) | -99,999.99% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -81.50% |
| Tangible Book Value (5 Year) | -0.61% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -99,999.99% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | -99,999.99% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -99,999.99% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -99,999.99% |
| Total Debt (5 Year) | 19.16% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 101.05% |
| EPS Change (Trailing Twelve Months) | -109.20% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 1 |
| Price to Tangible Book (Most Recent Quarter) | -100,000 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | 3.4M |
| Net Debt (Last Fiscal Year) | -3,098,990 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | -100,000 |
| Price to Sales (Trailing Twelve Months) | -100,000 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | 0 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | 0 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 0 |
| Price to Book (Most Recent Quarter) | 0 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | 8 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 2 |
| Current Ratio (Most Recent Quarter) | 1 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -12,377,850 |
| Free Cash Flow (Trailing Twelve Months) | -13,279,230 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -791 |
| Net Interest Coverage (Trailing Twelve Months) | -266 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 17 |
| Total Debt to Equity (Most Recent Quarter) | 9 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -256.35% |
| Return on Assets (Trailing Twelve Months) | -12.74% |
| Return on Assets (5 Year) | -295.92% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -507.58% |
| Return on Equity (Trailing Twelve Months) | -68.20% |
| Return on Equity (5 Year) | -18,438.87% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -471.06% |
| Return on Investment (Trailing Twelve Months) | -14.01% |
| Return on Investment (5 Year) | -1,599.51% |